15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering CytomX Therapeutics Inc, 8 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $10.00 to $16.00, a moderate spread. The average target of $12.63 sits 245% above the current $3.66. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.47 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Strong Buy
Strong Buy00%
Buy8100%
Hold00%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to CytomX Therapeutics Inc.
As of Sep, 8 of 8 firms rate CTMX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CTMX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.13 – $-0.06 · 7 analysts · -53% YoY
Next period, 7 analysts expect CytomX Therapeutics Inc to earn $-0.10 a share (range $-0.13 – $-0.06), versus $-0.22 a year earlier. Full-year consensus is $-0.39, growing to $-0.47 the year after.
REVENUE · NEXT QUARTER
$5.3M
Range $2.0M – $10.0M · 7 analysts · +704% YoY
Revenue is expected to reach $5.3M (range $2.0M – $10.0M), +704.4% year-over-year. Full-year consensus is $25.0M, rising to $25.3M next year.
Top analysts covering CytomX Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTMX.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$14.00+282.5% to target
Overall win rate
55%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #75
Buy
$11.00+200.5% to target
Overall win rate
51%
+ Follow
#3
Roger Song
Jefferies · Rank #101
Buy
$16.00+337.2% to target
Overall win rate
43%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$11.00+200.5% to target
Overall win rate
34%
+ Follow
#5
Joseph Catanzaro
Piper Sandler · Rank #272
Buy
$12.00+227.9% to target
Overall win rate
41%
+ Follow
CTMX stock forecast FAQ
What is CTMX's average 12-month price target?+
The 8 analysts with a live target average $12.63 for CytomX Therapeutics Inc over the next 12 months, ranging from a $16.00 high to a $10.00 low.
Is CTMX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 8 analyst ratings, 8 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CTMX?+
The Street-high target is $16.00 (Barclays), and the Street-low is $10.00 (Cantor Fitzgerald). The average of all 8 active targets is $12.63.
How many Wall Street analysts cover CTMX?+
8 analysts have an active rating on CytomX Therapeutics Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering CTMX?+
Among analysts who currently cover CTMX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $14.00 target.
What is CytomX Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.13 – $-0.06) across 7 analysts. Full-year EPS is projected at $-0.39, rising to $-0.47 the following year.
How much revenue is CytomX Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.3M (range $2.0M – $10.0M). Full-year revenue is projected at $25.0M, growing to $25.3M next year.
Have analysts been upgrading or downgrading CTMX lately?+
As of Sep, 8 of 8 firms rate CTMX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTMX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
